Reference ranges for total and calculated free and bioavailable testosterone in a young healthy women population with normal menstrual cycles or using oral contraception

Clinical Biochemistry

Volumn 45, Issue 1-2, 2012, Pages 148-150

  Pesant, Marie Hélène ^a   Desmarais, Guillaume ^a,b   Fink, Guy D ^b   Baillargeon, Jean Patrice ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Polycystic ovary syndrome; Reference value; Sex hormone binding globulin; Testosterone

Indexed keywords

SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ACNE; ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; MENSTRUAL CYCLE; ORAL CONTRACEPTION; PRIORITY JOURNAL; QUESTIONNAIRE; REFERENCE VALUE;

ADULT; BIOLOGICAL AVAILABILITY; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; MENSTRUAL CYCLE; MODELS, STATISTICAL; POLYCYSTIC OVARY SYNDROME; QUESTIONNAIRES; REFERENCE VALUES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 84855337774     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.10.001     Document Type: Article

References (10)

1. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J. Clin. Endocrinol. Metab. 1998, 83:3078-3082.
2. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 2006, 91:4237-4245.
3. Ayala C., Steinberger E., Smith K.D., Rodriguez-Rigau L.J., Petak S.M. Serum testosterone levels and reference ranges in reproductive-age women. Endocr. Pract. 1999, 5:322-329.
4. Ding E.L., Song Y., Manson J.E., Hunter D.J., Lee C.C., Rifai N., et al. Sex hormone-binding globulin and risk of type 2 diabetes. N. Engl. J. Med. 2009, 361:1152-1163.
5. Sodergard R., Backstrom T., Shanbhag V., Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J. Steroid Biochem. 1982, 16:801-810.
6. Miller K.K., Rosner W., Lee H., Hier J., Sesmilo G., Schoenfeld D., et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J. Clin. Endocrinol. Metab. 2004, 89:525-533.
7. Taponen S., Ahonkallio S., Martikainen H., Koivunen R., Ruokonen A., Sovio U., et al. Prevalence of polycystic ovaries in women with self-reported symptoms of oligomenorrhoea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. Hum. Reprod. 2004, 19:1083-1088.
8. Diamanti-Kandarakis E., Kouli C.R., Bergiele A.T., Filandra F.A., Tsianateli T.C., Spina G.G., et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metabol. 1999, 84:4006-4011.
9. Sinha-Hikim I., Arver S., Beall G., Shen R., Guerrero M., Sattler F., et al. The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women. J. Clin. Endocrinol. Metab. 1998, 83:1312-1318.
10. Wiegratz I., Kutschera E., Lee J.H., Moore C., Mellinger U., Winkler U.H., et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003, 67:25-32.